Fujifilm Diosynth Biotechnologies – a part of diversified Japanese conglomerate Fujifilm and a pharma contract development and manufacturing organisation (CDMO) – recently opened its microbial fermentation manufacturing facility in Billingham, UK.
This new facility triples existing microbial production throughput with the addition of a new production line equipped with 2 X 4,000-L fermenters, primary separations suite and a modular purification suite with an investment over 100 million GBP (around $130-mn). To support further expansion, the facility is built with the flexibility to accommodate new projects.
The company said the expansion was customised, in part, to support an un-named “large pharmaceutical partner” with a highly specialised ophthalmic therapeutic for wet age-related macular degeneration (AMD). Wet AMD is an eye disorder that causes blurred vision in the central vision.
“With the completion of this project, we are fulfilling our commitment with our partner, and supporting the commercialization of its ophthalmic therapeutic,” said Mr. Lars Petersen, President and CEO, Fujifilm Diosynth Biotechnologies.
Mr. Kenneth Bilenberg, the company’s Chief Operations Officer, noted that the move underscores the firm’s commitment to the BioCampus in Billingham where “we are progressing on expansions for our process development and quality labs as well as an expansion focusing on late stage clinical and commercial cell culture drug substance manufacturing.”


27 August, 2024 16:35:04 IST 

















